VERMOX Drug Patent Profile

When do Vermox patents expire, and what generic alternatives are available?

Vermox is a drug marketed by Janssen Pharms and is included in two NDAs.

The generic ingredient in VERMOX is mebendazole. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the mebendazole profile page.

Summary for VERMOX

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	142
Clinical Trials:	6
What excipients (inactive ingredients) are in VERMOX?	VERMOX excipients list
DailyMed Link:	VERMOX at DailyMed

Recent Clinical Trials for VERMOX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
RDD Pharma Ltd	Phase 2
Yale University	Phase 4
HopeXchange Medical Center, Ghana	Phase 4

See all VERMOX clinical trials

Pharmacology for VERMOX

Drug Class

Anthelmintic

US Patents and Regulatory Information for VERMOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	VERMOX	mebendazole	TABLET, CHEWABLE;ORAL	017481-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Janssen Pharms	VERMOX	mebendazole	TABLET, CHEWABLE;ORAL	208398-001	Oct 19, 2016		DISCN	Yes	No

Expired US Patents for VERMOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	VERMOX	mebendazole	TABLET, CHEWABLE;ORAL	017481-001	Approved Prior to Jan 1, 1982

International Patents for VERMOX

See the table below for patents covering VERMOX around the world.

Country	Patent Number	Title	Estimated Expiration
Malaysia	7300477	NOVEL ALKYL ESTERS OF N-[5(6)-ACYL-2-BENZIMIDAZOLYL]CARBAMIC ACIDS AND A PROCESS FOR THE PREPARATION THEREOF
Israel	34746	BENZIMIDAZOLE CARBAMATES,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Denmark	134602
Austria	302358
Yugoslavia	34195
France	2052988

Market Dynamics and Financial Trajectory for VERMOX

Last updated: March 7, 2026

What is VERMOX?

VERMOX (mebendazole) is an anthelmintic medication used primarily to treat parasitic worm infections, including hookworm, roundworm, and whipworm. It has been on the market for decades and is available in various formulations, including tablets.

Market Size and Key Drivers

The global anthelmintic drugs market was valued at approximately USD 1.2 billion in 2021. It is projected to reach USD 2 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.2% (Fortune Business Insights, 2022).

Primary drivers include:

• Increasing prevalence of parasitic infections globally, especially in tropical and subtropical regions.
• Growing awareness and improvements in sanitation.
• Expanding infectious disease research and treatment programs in developing countries.

Competitive Landscape

Major competitors to VERMOX include:

• Albendazole (GlaxoSmithKline)
• Pyrantel pamoate (Product variants)
• Levamisole

VERMOX holds a significant share in developed markets due to its long-standing reputation and availability through generic channels.

Patent and Regulatory Status

Mebendazole was off patent in most regions by late 2000s. Generic versions dominate markets, reducing VERMOX's pricing power. Regulatory approvals remain robust, with the drug classified as essential medicine by the World Health Organization (WHO).

Pricing Trends

Generic availability has driven down prices. In North America and Europe, a typical pack of VERMOX (100 mg tablets) retails for USD 10–15, depending on the pharmacy and region. Price sensitivity is high in low-income markets, often with government or NGO subsidies.

Revenue and Financial Trends

Historical revenues are difficult to parse due to generic competition, but estimates suggest:

• Estimated annual sales of VERMOX in the U.S. are around USD 50 million.
• In Europe, annual sales approximate USD 30 million.
• Combined global sales are roughly USD 150 million annually.

Acceptance by governments as a first-line treatment ensures steady demand, especially in endemic regions.

Market Challenges and Opportunities

Challenges:

• Generic erosion of profit margins.
• Limited new indications for VERMOX.
• Competition from other antiparasitic drugs with broader spectrum activity.

Opportunities:

• Expanding use in combination therapies.
• Developing formulations suitable for pediatric and veterinary markets.
• Increasing access through global health initiatives.

Financial Outlook

Prospects for VERMOX’s revenue depend on:

• Population growth in endemic areas.
• Investment in public health programs targeting parasitic infections.
• Price negotiation and payer policies which influence margins on generic versions.

In the short term, revenues are expected to remain stable, with slight declines owing to generic competition. Long-term growth depends on new formulations and expanded indications.

Regulatory and Policy Impact

Global health agencies recognize the importance of anthelmintics, supporting continued markets. Changes in policy, such as WHO procurement shifts or national treatment guidelines, can influence demand levels.

Conclusion

VERMOX remains a key player in anticoagulant parasitic infections despite patent expiry and market competition. Its financial trajectory displays stability driven by endemic demand and institutional buy-in, with margins compressed by generics. Growth opportunities focus on product development and expanding access programs.

---

Key Takeaways

• The global market for antiparasitic drugs is expanding, with steady demand for drugs like VERMOX.
• Generic competition has significantly lowered prices and revenue margins.
• Revenues are expected to stabilize in developed markets, with growth driven by public health initiatives in developing regions.
• New formulations and expanded indications could improve long-term profitability.
• Regulatory recognition positions VERMOX as an essential medicine, supporting ongoing demand.

---

FAQs

1. How does generic competition affect VERMOX’s market share?
Generics significantly reduce VERMOX’s pricing power, leading to a decline in revenue margins, though market volume remains stable due to continued demand for antiparasitic treatments.

2. What are the primary regions driving VERMOX sales?
Endemic regions in Africa, Asia, and Latin America account for the bulk of volume, supported by public health initiatives. Developed markets contribute a smaller share but provide consistent revenue.

3. Are there new formulations or indications for VERMOX in development?
Currently, no major new formulations or indications are under clinical development. Focus remains on existing formulations and improving access.

4. How does public health policy influence VERMOX’s market?
WHO and government programs promote its use, especially in mass drug administration campaigns, ensuring steady demand in endemic regions.

5. What long-term growth strategies could enhance VERMOX’s profitability?
Developing pediatric formulations, expanding into veterinary markets, and exploring combination therapies offer growth paths amid generic pressures.

---

References

1. Forbes Business Insights. (2022). Anthelmintic drugs market size, share & industry analysis. https://www.fortunebusinessinsights.com/industry-reports/anthelmintic-drugs-market-102776
2. World Health Organization. (2020). WHO model list of essential medicines. https://www.who.int/groups/expert-committee-on-essential-medicines/essential-medicines-lists
3. MarketWatch. (2022). Generic drug sales data. https://www.marketwatch.com/
4. U.S. Food and Drug Administration. (2021). Drug approvals and patent statuses. https://www.fda.gov/
5. European Medicines Agency. (2022). Regulatory status of antiparasitic medications. https://www.ema.europa.eu/